| Literature DB >> 27065471 |
Raquel Martín-García1, Guillermo Martín-Avila1, María De la Rubia-Marcos1, Raquel Maroto-Rodríguez1, Celia Ortega-Angulo1, María Teresa Carreras Rodriguez2, Francisco Abad Santos3, Ana Beatriz Gago Veiga2.
Abstract
BACKGROUND: Dementia is a neurodegenerative disease whose prevalence is rising, and the need for assistance to patients becomes indispensable. The different types of dementia and their treatments have been widely studied; however, the health status of caregivers also requires our attention.Entities:
Keywords: Burden; Caregivers; Dementia; Treatment
Year: 2016 PMID: 27065471 PMCID: PMC4821148 DOI: 10.1159/000442942
Source DB: PubMed Journal: Dement Geriatr Cogn Dis Extra ISSN: 1664-5464
Demographic data (average ± standard deviation or percentage)
| Features | Cases (n = 91) | Controls (n = 48) |
|---|---|---|
| Age, years | 67.96 ±12.61 | 66.45 ± 14.01 |
| Sex | ||
| Men | 36 (39.56%) | 19 (39.58%) |
| Women | 55 (60.43%) | 29 (60.42%) |
| Spanish nationality | 90 (98.90%) | 48 (100%) |
| Higher education | 36 (39.6%) | 13 (27.1%) |
Number (and percentage) of cases and controls receiving drugs from each of the drug groups
| Pharmacological group | Cases (n = 91) | Controls (n = 48) | p |
|---|---|---|---|
| Analgesics | 20 (22.2%) | 7 (14.6%) | 0.281 |
| Antihypertensive | 37 (40.7%) | 20 (41.7%) | 0.376 |
| Cholesterol-lowering drugs | 23 (25.3%) | 9 (18.8%) | 0.385 |
| Anxiolytics | 22 (24.2%) | 1 (2.1%) | 0.001 |
| Antidepressants | 12 (13.2%) | 0 | 0.008 |
| Osteoporosis medication | 8 (8.8%) | 5 (10.4%) | 0.754 |
| Gastroprotectives | 17 (18.7%) | 12 (25.0%) | 0.249 |
| Antiplatelets | 10 (11.0%) | 0 | 0.017 |
| Thyroid hormone | 4 (4.4%) | 2 (4.2%) | 0.950 |
| Anti-COPD | 5 (5.5%) | 6 (12.5%) | 0.146 |
| Antidiabetics | 9 (9.9%) | 7 (14.6%) | 0.410 |
| Prostate drugs | 4 (4.4%) | 2 (4.2%) | 0.950 |
| Anticoagulants | 4 (4.4%) | 6 (12.5%) | 0.079 |
| Others | 20 (22%) | 10 (20.8%) | 0.891 |
| (eyedrops, eardrops, antiarrhythmics, antiepileptics, antihistamines, magnesium, vitamin B and D, antipsychotics, antirheumatic, gallstone solvent, antimuscarinic) | (antiarrhythmics, hypouricemics, laxatives, oral contraceptives, antipsoriatics, antiepileptics, cataracts medications and prostate cancer medications) | ||
| No drugs | 17 (18.7%) | 9 (18.8%) | 0.992 |
Number (and percentage) of cases and controls receiving nonpharmacological treatments
| Cases (n = 91) | Controls (n = 48) | p | |
|---|---|---|---|
| Psychologist | 16 (17.6%) | 0 | 0.004 |
| Physiotherapist | 6 (6.6%) | 2 (4.2%) | 0.485 |
| Social worker | 15 (16.5%) | 1 (2.1%) | 0.021 |
| Support of an association | 26 (28.6%) | 0 | 0.000 |
| Others | 1 (1.1%) | 0 | 0.466 |
| None | 49 (53.8%) | 45 (93.8%) | 0.000 |
| No answer | 1 (1.1%) | 0 | 1.000 |
Relationship between subjective burden and consumption of analgesics, anxiolytics, antidepressants and antiplatelets in cases
| Drugs | Burden | |||
|---|---|---|---|---|
| yes (n = 61) | no (n = 21) | no answer (n = 9) | p | |
| Analgesics | 14 (23.3%) | 4 (19.0%) | 2 (22.2%) | 0.921 |
| Anxiolytics | 19 (31.1%) | 1 (4.8%) | 2 (22.2%) | 0.05 |
| Antidepressants | 9 (14.8%) | 2 (9.5%) | 1 (11.1%) | 0.814 |
| Antiplatelets | 6 (9.8%) | 3 (14.3%) | 1 (11.1%) | 0.854 |
Relationship between behavioral changes and consumption of different treatments
| Drugs | Behavioral changes | |||||
|---|---|---|---|---|---|---|
| positive symptoms (n = 44) | negative symptoms (n = 21) | positive and negative symptoms (n = 9) | total with behavioral changes (n = 56) | without any behavioral changes (n = 5) | p (total behavioral change vs. no change) | |
| Analgesics | 12 (27.3%) | 4 (20%) | 2 (22.2%) | 14 (25.5%) | 6 (17.1%) | 0.355 |
| Anxiolytics | 17 (38.6%) | 6 (28.6%) | 4 (44.4%) | 19 (33.9%) | 3 (8.6%) | 0.006 |
| Antidepressants | 8 (18.2%) | 4 (19.0%) | 2 (22.2%) | 10 (17.9%) | 2 (5.7%) | 0.096 |
| Antiplatelets | 3 (6.8%) | 0 | 0 | 3 (5.4%) | 7 (20.0%) | 0.03 |